The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a huge mover today! The stock increased 5.61% or $1.5 on November 23, hitting $28.22. About 1.84M shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 17.05% since April 22, 2016 and is downtrending. It has underperformed by 22.46% the S&P500.
The move comes after 6 months positive chart setup for the $3.19B company. It was reported on Nov, 24 by Barchart.com. We have $30.48 PT which if reached, will make NASDAQ:ACAD worth $255.20 million more.
Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on March, 6. They expect $-0.64 earnings per share, down 42.22% or $0.19 from last year’s $-0.45 per share. After $-0.61 actual earnings per share reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 4.92% negative EPS growth.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage
Out of 7 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. ACADIA Pharmaceuticals has been the topic of 16 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Piper Jaffray downgraded the shares of ACAD in a report on Friday, August 7 to “Neutral” rating. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Overweight” rating by Piper Jaffray on Friday, January 22. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Overweight” rating by Piper Jaffray on Friday, August 7. The rating was upgraded by Bank of America on Tuesday, November 8 to “Buy”. The firm earned “Neutral” rating on Wednesday, October 19 by Roth Capital. The rating was maintained by Needham with “Buy” on Friday, August 7. The rating was maintained by JP Morgan with “Buy” on Friday, September 4. Piper Jaffray upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating on Thursday, August 27. Piper Jaffray has “Neutral” rating and $48.0 price target. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Neutral” rating by Goldman Sachs on Friday, November 11. The firm has “Market Perform” rating given on Tuesday, May 3 by Leerink Swann.
According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”
Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.18, from 1.02 in 2016Q1. The ratio improved, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
The New York-based Lombard Odier Asset Mngmt (Usa) has invested 0.29% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Rhenman And Prtn Asset Mgmt Ab reported 50,000 shares or 0.29% of all its holdings. Alliancebernstein L P has 0% invested in the company for 134,270 shares. Sg Americas Secs Limited Liability Company reported 12,502 shares or 0% of all its holdings. Finemark Natl Bank owns 235 shares or 0% of their US portfolio. Hwg Hldgs Ltd Partnership holds 289,380 shares or 8.72% of its portfolio. Victory Cap Management holds 443 shares or 0% of its portfolio. Blackrock Fund Advsrs has 0.02% invested in the company for 2.34 million shares. Sectoral Asset Inc accumulated 29,582 shares or 0.1% of the stock. Garrison Bradford And Assocs Incorporated holds 70,100 shares or 2.23% of its portfolio. Credit Suisse Ag holds 182,537 shares or 0.01% of its portfolio. Perceptive Advsrs Lc holds 0.37% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 165,240 shares. Bnp Paribas Arbitrage holds 20,654 shares or 0% of its portfolio. Mark Sheptoff Planning Limited Liability Company, a Connecticut-based fund reported 500 shares. National Bank & Trust Of New York Mellon Corp reported 404,944 shares or 0% of all its holdings.
Insider Transactions: Since July 11, 2016, the stock had 2 buys, and 2 sales for $42.17 million net activity. Baity Glenn sold 10,200 shares worth $306,687. BAKER BROS. ADVISORS LP bought 1.30M shares worth $43.00M. 1,000 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares with value of $32,970 were bought by HARRIGAN EDMUND.
ACAD Company Profile
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.